Provectus Pharmaceuticals announces consistent results for PV-10
Provectus Pharmaceuticals announced that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial of PV-10 showed comparable trends to Phase 1 survival data. Survival data for the Phase 1 study of PV-10 for metastatic melanoma continues to show markedly longer overall and disease specific survival for subjects that were responsive to PV-10 relative to those who did not experience a robust response. Survival data was available through early November. Additionally, several subjects in the responsive group also exhibited one or more indicators of the bystander effect including the first evidence of regression of visceral metastases in two of five subjects in this group who had documented visceral metastases at enrollment. :theflyonthewall.com
News For PVCT From The Last 14 Days
Check below for free stories on PVCT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
